Primary Immune Thrombocytopenia
Conditions
Keywords
ITP, Rituximab, Efficacy, Anti-CD20, Regimen
Brief summary
The aim of this large French multicentric retrospective study was to compare the efficacy and safety of two (the standard and the Rheumatoid arthritis) rituximab regimens in adult's immune thrombocytopenia .
Detailed description
Every adult (age ≥ 18 years) seen in one of the 3 participating centre (dijon, Marseille, Mondor) over a 7-year period (2005-2012) with a definite diagnosis of primary ITP according to the American Society Hematology guidelines who received RTX regardless the regimen could be included.
Interventions
None listed
Sponsors
Henri Mondor University Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Primary ITP * Age \> 18 years
Exclusion criteria
* Secondary ITP * Age \< 18 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The primary end point of the study was to assess the response rate to treatment 1 year after the first rituximab infusion. | one year | A complete response (CR) was defined as a platelet count \>100 x 109/l and a response (R): by a platelet count \>30 x 109/l with a least a doubling of the baseline value without any rescue intervention within 8 weeks before assessment, and no response (NR) was defined as a platelet count lower than 30 x 109/ |
Secondary
| Measure | Time frame |
|---|---|
| The response rate 3months, and at the last follow-up after the first rituximab infusion. Variable associated with RTX response. | 3 months, one year, last follow-up |
Outcome results
None listed